Leith Wheeler Investment Counsel Ltd. Sells 450 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Leith Wheeler Investment Counsel Ltd. reduced its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) by 0.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 226,480 shares of the company’s stock after selling 450 shares during the period. Henry Schein makes up approximately 2.7% of Leith Wheeler Investment Counsel Ltd.’s holdings, making the stock its 2nd biggest holding. Leith Wheeler Investment Counsel Ltd. owned 0.17% of Henry Schein worth $18,089,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. DNB Asset Management AS raised its holdings in Henry Schein by 2.5% during the 4th quarter. DNB Asset Management AS now owns 44,032 shares of the company’s stock worth $3,517,000 after buying an additional 1,088 shares during the period. Bank of New Hampshire grew its stake in shares of Henry Schein by 1.6% during the 4th quarter. Bank of New Hampshire now owns 14,822 shares of the company’s stock worth $1,184,000 after acquiring an additional 239 shares in the last quarter. Yousif Capital Management LLC grew its stake in shares of Henry Schein by 49.4% during the 4th quarter. Yousif Capital Management LLC now owns 36,098 shares of the company’s stock worth $2,883,000 after acquiring an additional 11,939 shares in the last quarter. Bridgefront Capital LLC bought a new position in shares of Henry Schein during the 3rd quarter worth approximately $290,000. Finally, Aurora Investment Counsel bought a new position in shares of Henry Schein during the 3rd quarter worth approximately $1,362,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Down 1.1 %

Shares of NASDAQ HSIC traded down $0.88 during mid-day trading on Friday, reaching $77.27. 1,253,732 shares of the company’s stock traded hands, compared to its average volume of 881,812. The stock has a market cap of $10.14 billion, a P/E ratio of 19.86, a PEG ratio of 1.81 and a beta of 0.80. The business has a 50-day simple moving average of $81.94 and a 200 day simple moving average of $77.29. Henry Schein, Inc. has a 1-year low of $64.75 and a 1-year high of $92.68. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.79 and a quick ratio of 0.91.

Henry Schein (NASDAQ:HSIC – Get Rating) last announced its quarterly earnings results on Thursday, February 16th. The company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.21 by $0.14. The company had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a return on equity of 15.79% and a net margin of 4.25%. Henry Schein’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.07 EPS. On average, analysts expect that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kurt P. Kuehn sold 1,909 shares of the business’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total transaction of $147,871.14. Following the completion of the transaction, the director now directly owns 15,675 shares in the company, valued at approximately $1,214,185.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Lorelei Mcglynn sold 15,341 shares of the business’s stock in a transaction dated Tuesday, December 20th. The shares were sold at an average price of $80.70, for a total value of $1,238,018.70. Following the completion of the sale, the senior vice president now owns 73,753 shares in the company, valued at approximately $5,951,867.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Kurt P. Kuehn sold 1,909 shares of the business’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $77.46, for a total transaction of $147,871.14. Following the transaction, the director now owns 15,675 shares of the company’s stock, valued at approximately $1,214,185.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,495 shares of company stock valued at $2,442,276. 1.00% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HSIC shares. UBS Group raised their price target on shares of Henry Schein from $75.00 to $82.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 7th. Credit Suisse Group decreased their target price on shares of Henry Schein from $99.00 to $97.00 and set an “outperform” rating for the company in a research note on Tuesday, February 28th. StockNews.com started coverage on shares of Henry Schein in a research report on Thursday. They set a “buy” rating for the company. Barrington Research reduced their price objective on shares of Henry Schein from $99.00 to $92.00 and set an “outperform” rating for the company in a research report on Friday, February 17th. Finally, Piper Sandler lifted their target price on Henry Schein from $85.00 to $97.00 and gave the stock an “overweight” rating in a report on Monday, February 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $85.89.

Henry Schein Company Profile

(Get Rating)

Henry Schein, Inc engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, laboratory, small and large equipment repair services, branded and generic pharmaceuticals, vaccines, surgical, diagnostic tests, infection-control products, and vitamins.